DiaMedica Therapeutics
DMACDiaMedica Therapeutics is a clinical-stage biopharmaceutical company focused on developing novel recombinant protein therapies for severe ischemic diseases.
Earnings
Next report
Nov 11, 2026 (in 2 months)Competitors
By market cap
By revenue growth
By net margin
Profile
DiaMedica Therapeutics is a clinical-stage biopharmaceutical company focused on developing novel recombinant protein therapies for severe ischemic diseases. The company's lead candidate, DM199, is a synthetic form of the human tissue kallikrein-1 (KLK1) protein designed to improve microcirculatory blood flow and endothelial health. Its primary clinical programs target acute ischemic stroke (AIS), preeclampsia (PE), and fetal growth restriction (FGR).
DiaMedica is a pioneer in developing the first recombinant form of human tissue kallikrein-1, aiming to replace urinary- and porcine-derived versions currently used in Asian markets.
FAQ
- What is DiaMedica Therapeutics's market cap?
- DiaMedica Therapeutics (DMAC) has a market capitalization of $361.3M and trades on NASDAQ.
- Who are DiaMedica Therapeutics's competitors?
- DiaMedica Therapeutics's key competitors include Biogen, Alzamend Neuro, Inc. Common Stock, vTv Therapeutics Inc. Class A Common Stock, and others. These companies compete in similar markets and product categories.
- Who does DiaMedica Therapeutics partner with?
- DiaMedica Therapeutics's notable partners include Catalent Pharma Solutions, LLC, Tygerberg Hospital, Tech-pool BioPharma, and others.
- What subsidiaries does DiaMedica Therapeutics have?
- DiaMedica Therapeutics's subsidiaries include DiaMedica USA Inc..
- Where is DiaMedica Therapeutics headquartered?
- DiaMedica Therapeutics is headquartered in United States of America and employs approximately 19 people. It has been publicly traded since 2007.